Drug Screening for Huntington's Disease and other Neurodegenerative Disorders

Publisher： Bentham Science Publishers

E-ISSN： 1874-4702|3|3|164-173

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.3, Iss.3, 2010-11, pp. : 164-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tocopherol (Vitamin E) in Alzheimer’s Disease and Other Neurodegenerative Disorders

By Karen Berman   Henry Brodaty  

CNS Drugs, Vol. 18, Iss. 12, 2004-01 ,pp. : 807-825

Adis International

Access to resources Recommend Favorite

Tau protein as a therapeutic target in Alzheimer’s disease and other neurodegenerative disorders

By Larner A.J.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 10, 1999-10 ,pp. : 1359-1370

Informa Healthcare

Access to resources Recommend Favorite

Emerging drug therapies in Huntington's disease

By Mason Sarah L   Barker Roger A  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 2, 2009-06 ,pp. : 273-297

Informa Healthcare

Access to resources Recommend Favorite

Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments

By Trojanowski John Q   Smith Amos B   Huryn Donna   Lee Virginia M-Y  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 5, 2005-05 ,pp. : 683-686

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer’s disease and other neurodegenerative disorders

By Castro A.   Martinez A.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 10, 2000-10 ,pp. : 1519-1527

Informa Healthcare

Access to resources Recommend Favorite